Skip to main content
. 2020 Dec 6;7(1):e585. doi: 10.1002/ams2.585

Fig. 2.

Fig. 2

Timeline of clinical features and laboratory findings in a 63‐year‐old man with respiratory failure due to COVID‐19 pneumonia. Nafamostat was discontinued after 4 days (black arrow) due to hyperkalemia and hemothorax. ECMO, extracorporeal membrane oxygenation.